Genetic Disorders · Congenital Disorders of GlycosylationTrial Updateclinicalmid-term

Safety and Tolerability Study of NMN in DHDDS-CDG Patients Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:33:52 AM

Assessment confidence: 77% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of this clinical trial on NMN for DHDDS-CDG patients is significant as it may pave the way for new treatment options in genetic disorders. The outcomes could influence clinical guidelines and market dynamics for NMN, making it essential for pharma strategy teams to stay informed. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)) supports the near-term read. Assessment grounded in 11 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this trial to evaluate the potential for NMN in their product offerings for genetic disorders. The strongest clinical anchor is Assessing the Safety and Tolerability of NMN in DHDDS-CDG (ClinicalTrials.gov), entity match (dhdds-cdg). In rare disease, 8 regulatory and 1 competitive items passed relevance filtering for DHDDS-CDG.

Competitive Pressure

The most relevant competitive pressure comes from Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study (Humanexa Signals) — sponsor/company relevance (merck). This study may provide insights into the use of NMN as a therapeutic option, potentially influencing treatment guidelines and market interest in NMN for genetic disorders.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). The trial findings may lead to updated recommendations or approvals for NMN, affecting compliance and labeling requirements for related products.

Key Risks

Elevated medium regulatory exposure for DHDDS-CDG could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Positive trial results could enhance NMN's market positioning and open new revenue streams in the genetic disorders segment, impacting competitive strategies.
Portfolio teams should monitor the outcomes of this trial to evaluate the potential for NMN in their product offerings for genetic disorders.

What Would Change This Assessment

This becomes more urgent if Key milestones include trial results and any subsequent recommendations for NMN use in clinical practice.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

Assessing the Safety and Tolerability of NMN in DHDDS-CDG
ClinicalTrials.govmedium relevance
Entity match (dhdds-cdg)
FDA document
View source
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Ce
ClinicalTrials.govmedium relevance
Mechanism alignment (IO )
FDA document
View source
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)

Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

DHDDS-CDG

Commercial impact

medium

Positive trial results could enhance NMN's market positioning and open new revenue streams in the genetic disorders segment, impacting competitive strategies.

Regulatory impact

medium

The trial findings may lead to updated recommendations or approvals for NMN, affecting compliance and labeling requirements for related products.

What to watch

Key milestones include trial results and any subsequent recommendations for NMN use in clinical practice.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.